Researchers are now able to detect “toxic” small aggregates of a particular protein in the blood of people with Alzheimer’s disease, as well as in those showing no signs of cognitive impairment at the time the blood sample was taken, but who developed it at a later date.

The blood test picks up oligomers – or small, misfolded aggregates – of the amyloid beta protein, which scientists believe triggers the development of Alzheimer’s, paving the way to earlier identification and treatment of the disease

Generally, patients receive an Alzheimer’s diagnosis only after they exhibit well-known signs of the disease, like memory loss. By then, the best treatment options simply slow further progression of symptoms. …more